13D Filing: Versant Venture Capital IV, L.P. and Crispr Therapeutics AG (CRSP)

Page 17 of 18

Page 17 of 18 – SEC Filing

 

Exhibit 1

 

Joint Filing Agreement

 

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of CRISPR Therapeutics AG shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

 

September 15, 2017

 

 

 

Versant Venture Capital IV, L.P.

 

 

 

By: Versant Ventures IV, LLC

 

Its: General Partner

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

Versant Side Fund IV, L.P.

 

 

 

By: Versant Ventures IV, LLC

 

Its: General Partner

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

Versant Ventures IV, LLC

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

 

 

Versant Venture Capital V, L.P.

 

 

 

By: Versant Ventures V, LLC

 

Its: General Partner

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

Versant Affiliates Fund V, L.P.

 

 

 

By: Versant Ventures V, LLC

 

Its: General Partner

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

Versant Ophthalmic Affiliates Fund I, L.P.

 

 

 

By: Versant Ventures V, LLC

 

Its: General Partner

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

 

Versant Ventures V, LLC

 

 

 

 

 

By:

/s/ Robin L. Praeger

 

 

Robin L. Praeger, Managing Director

 

 

17


Follow Crispr Therapeutics Ag (NASDAQ:CRSP)

Page 17 of 18